Fig. 7: EB-42168 demonstrates selective inhibition of pSer935 LRRK2 in heterozygous G2019S LRRK2 PD patient-derived LCLs relative to healthy controls.
From: G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
a Representative western blot of PD patient-derived LRRK2 G2019S carriers and age-matched healthy controls LCLs treated with DMSO, 10 nM, or 100 nM MLi-2 for 2 h and assessed for LRRK2 pSer935 and full-length LRRK2. b Representative western blot of PD patient-derived LRRK2 G2019S carriers and age-matched healthy controls LCLs treated with DMSO, 10 nM, or 100 nM EB-42168 for 2 h and assessed for LRRK2 pSer935 and full-length LRRK2. c Quantification of western blots demonstrate an 85% and 95% decrease in LRRK2 pSer935 levels in MLi-2 treated LRRK2 G2019S PD patient-derived and age-matched healthy controls. d Quantification of western blots demonstrate no change in LRRK2 pSer935 levels with EB-42168 treatment in healthy controls. Quantification of western blots demonstrate a 25% and 40% decrease in LRRK2 pSer935 levels with 10 nM and 100 nM EB-42168 in PD patient-derived LRRK2 G2019S carriers. Data are presented as mean ± SEM. (**p < 0.01 determined by two-way ANOVA).
